Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment: 2009-2016

Historic Asset Writedowns and Impairment for Lineage Cell Therapeutics (LCTX) over the last 7 years, with Dec 2016 value amounting to $950,000.

  • Lineage Cell Therapeutics' Asset Writedowns and Impairment was N/A to $148,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $559,000, marking a year-over-year change of. This contributed to the annual value of $950,000 for FY2016, which is N/A change from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Asset Writedowns and Impairment of $950,000 as of FY2016, which was up 6,037.50% from -$16,000 recorded in FY2014.
  • In the past 5 years, Lineage Cell Therapeutics' Asset Writedowns and Impairment registered a high of $950,000 during FY2016, and its lowest value of -$16,000 during FY2014.
  • In the last 2 years, Lineage Cell Therapeutics' Asset Writedowns and Impairment had a median value of $467,000 in 2014 and averaged $467,000.
  • Data for Lineage Cell Therapeutics' Asset Writedowns and Impairment shows a maximum YoY crashed of 220.00% (in 2014) over the last 5 years.
  • Lineage Cell Therapeutics' Asset Writedowns and Impairment (Yearly) stood at $19,681 in 2012, then crashed by 125.41% to -$5,000 in 2013, then plummeted by 220.00% to -$16,000 in 2014, then reached $950,000 in 2016.